Physician profile
Michael C Ong
NPI 1639162969
$12,709.99
in general payments reported to CMS, 2019-2025
36 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,943 · 2020: $1,823 · 2021: $2,663 · 2022: $2,546 · 2023: $2,268 · 2024: $780 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.85 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,400.21 | 2019-2024 | Wegovy, Saxenda |
| Glaxosmithkline, LLC. | $1,771.52 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,249.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,054.79 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $965.97 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $822.68 | 2019-2022 | |
| Lilly USA, LLC | $683.76 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.10 | 2019-2024 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $535.13 | 2019-2024 | |
| Daiichi Sankyo INC. | $404.81 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $345.10 | 2019-2023 | Verquvo, Steglatro |
| Kowa Pharmaceuticals America, INC. | $213.12 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $209.17 | 2022-2025 | |
| Abbvie INC. | $194.14 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.33 | 2020-2025 | Xifaxan, Trulance, Relistor |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $175.33 | 2019-2024 | Linzess |
| Amarin Pharma, INC. | $136.49 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.90 | 2019-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $95.69 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $63.91 | 2020-2024 | Veozah |
| Currax Pharmaceuticals LLC | $60.37 | 2022-2023 | Onzetra Xsail, Contrave |
| Grifols USA, LLC | $55.97 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $51.46 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.97 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $30.36 | 2023 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $29.74 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $29.05 | 2019 | |
| Horizon Therapeutics Plc | $27.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.21 | 2019 | |
| Allergan, INC. | $21.22 | 2019 | |
| Cequr Corporation | $19.20 | 2022-2023 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $18.82 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.43 | 2024 | Voquezna |
| Abbott Laboratories | $16.85 | 2024 | Freestyle Libre 3 |
| Theracosbio, LLC | $16.10 | 2024 | Brenzavvy |
| Redhill Biopharma INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.